Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines. An unusual study presented at the European Society of Cardiology (ESC) congress in ...

With competition in the GLP-1 category increasingly cutthroat, Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy was better than Eli Lilly's rival Zepbound at ...

A new meta-analysis from Mattia Galli, MD, PhD, et al., of 21 trials using eight different GLP1-RAs and with nearly 100,000 patients found "conclusive high-certainty evidence" that, vs. controls, the ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...